Bruker (Bruker) ROCE % : 9.50% (As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Bruker ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bruker's annualized ROCE % for the quarter that ended in Mar. 2024 was 9.50%.

Bruker ROCE % Historical Data

The historical data trend for Bruker's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bruker ROCE % Chart

Bruker Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

16.22

10.96

16.42

15.90

19.52

Bruker Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															16.38	11.79	17.73	33.86	9.50

Bruker ROCE % Calculation

Bruker's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	560.6	/	( ( (3611.8 - 914.3)	+	(4249.9 - 1202.1) )	/ 2 )
	=	560.6	/	( (2697.5	+	3047.8)	/ 2 )
	=	560.6	/	2872.65
	=	19.52 %

Bruker's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	302.8	/	( ( (4249.9 - 1202.1)	+	(4506.4 - 1182.5) )	/ 2 )
	=	302.8	/	( ( 3047.8	+	3323.9 )	/ 2 )
	=	302.8	/	3185.85
	=	9.50 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Bruker (NAS:BRKR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bruker ROCE % Related Terms

Thank you for viewing the detailed overview of Bruker's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bruker (Bruker) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bruker Corp (NAS:BRKR) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BKD:Germany

Address

40 Manning Road, Billerica, MA, USA, 01821

Website

https://www.bruker.com

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives a majority of its revenue from Europe.

Executives

Frank H Laukien	director, 10 percent owner, officer: CEO, President	C/O BRUKER DALTONICS, 40 MANNING ROAD, BILLERICA MA 01821
Marc A Kastner	director	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Cynthia M Friend	director	C/O BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Richard A Packer	director	9 KENDALL DRIVE, WESTBOROUGH MA 01581
Philip Ma	director	C/O BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Mark Munch	officer: Pres. Bruker Nano Inc.	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Juergen Srega	officer: Group President Bruker CALID	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Burkhard Prause	officer: Pres. & CEO, Bruker EST	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Bonnie H Anderson	director	6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Martin Gilles Gerard Jean	director	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Falko Busse	officer: President, BioSpin Group	40 MANNING ROAD, BILLERICA MA 01821
Gerald N Herman	officer: Vice President, Corp Contr.	55 EXECUTIVE DRIVE, HUDSON NH 03051
Ingen Chris Van	director	395 PAGE MILL RD, MS A3 18, PALO ALTO CA 94306
Richard Kniss	director	395 PAGE MILL RD, MS A3 18, PALO ALTO CA 94306
Adelene Q Perkins	director	C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139